Several phase I trials assessing the safety of IGF-1R targeted agents demonstrated clinical activity in two advanced breast cancer patients receiving AVE 1642 and one treated by AMG 479 as single agent [51, 52]. This evidence concerns the gene IGF1R and breast carcinoma.